Drugs / HL301
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 23 trials | ||||||
| Phase 2 | NCT04632342 | Nov 2020 → Jan 2022 | lung cancer, radiation pneumonitis | Hanlim Pharm. Co., Ltd. | Unknown | No outcome recorded |
| Phase 2 | NCT03309800 | Mar → Aug 2017 | bronchitis | Hanlim Pharm. Co., Ltd. | Completed | No outcome recorded |
| Phase 2 | NCT02250027 | Mar → Jul 2014 | chronic bronchitis | Hanlim Pharm. Co., Ltd. | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT03654196 | Mar → Sep 2018 | bronchitis | Hanlim Pharm. Co., Ltd. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HL301 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03654196 ↗ |
| Route | Oral | “7 Days Oral Administration” NCT02250027 ↗ |